Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence

Gibson, Caitlin M.; Basto, Amanda N.; Howard, Meredith L.

doi:10.1177/1060028017737095

Cited by 16 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCTs and meta-analysis have demonstrated the safety and efficacy of DOAC in patients undergoing ECV [7][8][9][26][27][28]. Our results are in line with the outcome of the 3 RCTs focusing on pericardioversion DOAC (Appendix C).…”

Section: J O U R N a L P R E -P R O O Fsupporting

confidence: 85%

Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population

Heide¹,

Wit

Bhagwandien

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: J O U R N a L P R E -P R O O Fsupporting

confidence: 85%

Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population

Heide¹,

Wit

Bhagwandien

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…The trial showed a significant reduction with apixaban in strokes (0% vs. 0.8%) and in major bleeding (0.4% vs. 0.8%) at 30 days compared to warfarin. The favorable clinical profile of NOACs in patients undergoing CV has also been confirmed in a recent metanalysis [59,60] and in real-world studies [61,62,63,64,65,66].…”

Section: Prevention and Treatment Of Left Atrial Appendage Thrombosismentioning

confidence: 65%

Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion

et al. 2019

View full text Add to dashboard Cite

Atrial fibrillation is the most common cardiac arrhythmia and is associated with an increased risk of stroke and thromboembolic complications. A rhythm control strategy with both electrical and pharmacological cardioversion is recommended for patients with symptomatic atrial fibrillation. Anticoagulant therapy for 3–4 weeks prior to cardioversion is recommended in order to avoid thromboembolic events deriving from restoring sinus rhythm. Transesophageal echocardiography has a pivotal role in this setting, excluding the presence of left atrial appendage thrombus before cardioversion. The aim of this review is to discuss the epidemiology and risk factors for left atrial appendage thrombosis, the role of echocardiography in the decision making before cardioversion, and the efficacy of different anticoagulant regimens on the detection and treatment of left atrial appendage thrombosis.

show abstract

“…Finally, DOACs demonstrated good predictable onset of anticoagulation (since 1 to maximum 4 h) compared with 48 to 72 h for warfarin and up to 5 to 7 days to reach steady state [36,37]. In a very interesting random-effects meta-analysis performed by Brunetti et al [38], a total of 8564 patients undergoing both electrical and pharmacologic cardioversions for NVAF were included observing, one more time, the effectiveness and safety of DOACs in patients undergoing NVAF.…”

Section: Discussionmentioning

confidence: 99%

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion

et al. 2019

View full text Add to dashboard Cite

Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real “epidemic phenomenon”. Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in bleedings and increase in the safety and quality of life of patients.

show abstract

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence

Abstract: DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion.

Cited by 16 publications

References 40 publications

Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population

Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population

Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion

Contact Info

Product

Resources

About